What Rapid Micro Biosystems, Inc. reported on August 7, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
What Rapid Micro Biosystems, Inc. expects
Rapid Micro Biosystems, Inc.’s own guidance, from its results release of August 7, 2026. It is the company’s statement of what it expects, not a forecast of ours.
Fiscal year 2026 · ending around December 2026
- Revenue
- $37M to $41M
- Gross margin
- about 20.0%
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|
| Total Revenue | $8.1M | $7.3M | +10.91% |
| Profit | -$12.9M | -$11.9M | -8.98% |
| Profit per share | -$0.27 | -$0.27 | 0.00% |
| Free Cash Flow | -$12.5M | -$10.1M | -23.97% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingRapid Micro Biosystems, Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What management said
“Our second quarter results reflect continued execution against the strategic and financial priorities we outlined at the beginning of the year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$2.08
Aug 6, 2026
Close after
$1.71
Aug 10, 2026
Move
-17.79%
1.44M shares traded, against a normal 200.67K
What Rapid Micro Biosystems, Inc. does
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Rapid Micro Biosystems, Inc.’s Item 2.02 8-K filed August 7, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
